Browse > Article
http://dx.doi.org/10.4110/in.2010.10.3.104

Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b+Gr-1+ Myeloid-derived Suppressor Cells  

Lee, Jung-Mi (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Seo, Jeong-Hwan (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Kim, Yeon-Jeong (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Kim, Yun-Sun (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Ko, Hyun-Jeong (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Kang, Chang-Yuil (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Publication Information
IMMUNE NETWORK / v.10, no.3, 2010 , pp. 104-108 More about this Journal
Abstract
CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T cells. However, agonistic anti-CD137 monoclonal antibody (mAb) treatment can suppress $CD4^+$ T cells, ameliorating autoimmune diseases, whereas it induces activation of $CD8^+$ T cells, resulting in diverse therapeutic activity in cancer, viral infection. To investigate the CD137-mediated T cell suppression mechanism, we examined whether anti-CD137 mAb treatment could affect $CD11b^+Gr-1^+$ myeloid-derived suppressor cells (MDSCs). Intriguingly, anti-CD137 mAb injection significantly increased $CD11b^+Gr-1^+$ cells, peaking at days 5 to 10 and continuing for at least 25 days. Furthermore, this cell population could suppress both $CD8^+$ T cells and $CD4^+$ T cells. Thus, this study demonstrated that, for the first time, anti-CD137 mAb treatment could induce $CD11b^+Gr-1^+$ MDSCs under normal conditions, suggesting a possible relationship between myeloid cell induction and CD137-mediated immune suppression.
Keywords
CD137; $CD11b^+Gr-1^+$ cells; Myeloid-derived suppressor cells; Immunosuppression;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Vinay DS, Cha K, Kwon BS: Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 84;726-736, 2006   DOI   ScienceOn
2 Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, Lynch DH: 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 169;1792-1800, 2002   DOI
3 Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH: NK and CD8＋ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 109;499-506, 2004   DOI   ScienceOn
4 Halstead ES, Mueller YM, Altman JD, Katsikis PD: In vivo stimulation of CD137 broadens primary antiviral CD8＋ T cell responses. Nat Immunol 3;536-541, 2002   DOI   ScienceOn
5 Hong HJ, Lee JW, Park SS, Kang YJ, Chang SY, Kim KM, Kim JO, Murthy KK, Payne JS, Yoon SK, Park MJ, Kim IC, Kim JG, Kang CY: A humanized anti--4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother 23;613-621, 2000   DOI   ScienceOn
6 Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX: Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8;1405- 1413, 2002   DOI   ScienceOn
7 Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX: Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168;1457-1465, 2002
8 Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, Chander PN, Bapat AS, Yan XJ, Chiorazzi N, Hoffmann MK, Mittler RS: CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 111;1505-1518, 2003
9 Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS: 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10;1088-1094, 2004   DOI   ScienceOn
10 Foell JL, Diez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, Hoffmann MK, Mittler RS, Dannecker GE: Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen- induced arthritis and establishes lasting disease resistance. Immunology 113;89-98, 2004   DOI   ScienceOn
11 Kim J, Choi WS, La S, Suh JH, Kim BS, Cho HR, Kwon BS, Kwon B: Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4＋ T cells. Blood 105; 2206-2213, 2005
12 Kim YH, Seo SK, Choi BK, Kang WJ, Kim CH, Lee SK, Kwon BS: 4-1BB costimulation enhances HSV-1-specific CD8＋ T cell responses by the induction of CD11c＋CD8＋ T cells. Cell Immunol 238;76-86, 2005   DOI   ScienceOn
13 Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9;162-174, 2009   DOI   ScienceOn
14 Vinay DS, Kim CH, Choi BK, Kwon BS: Origins and functional basis of regulatory CD11c＋CD8＋ T cells. Eur J Immunol 39;1552-1563, 2009   DOI   ScienceOn
15 Lee SW, Park Y, So T, Kwon BS, Cheroutre H, Mittler RS, Croft M: Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol 9;917-926, 2008
16 Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS: Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 178;4194-4213, 2007
17 Dubrot J, Azpilikueta A, Alfaro C, Murillo O, Arina A, Berraondo P, Hervas-Stubbs S, Melero I: Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells. Immunologia 26;121-126, 2007
18 Wang C, Lin GH, McPherson AJ, Watts TH: Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 229;192-215, 2009   DOI   ScienceOn